Elevance Health, Inc. $ELV Shares Bought by B. Metzler seel. Sohn & Co. AG

Key Points

• B. Metzler seel. Sohn & Co. AG raised its stake in Elevance Health by 9.9%, now holding 22,404 shares valued at approximately $9.75 million.
• Elevance Health's stock has received mixed ratings from analysts, with twelve ratings categorized as "Buy" and six as "Hold," alongside a revised target price from Royal Bank of Canada set at $478.00.
• The company reported $8.84 EPS for the recent quarter, missing expectations, but revenue increased 14.3% year-over-year, totaling $49.42 billion.

B. Metzler seel. Sohn & Co. AG increased its stake in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 9.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 22,404 shares of the company's stock after buying an additional 2,011 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in Elevance Health were worth $9,745,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in ELV. Nuveen LLC purchased a new stake in Elevance Health in the 1st quarter valued at approximately $789,943,000. GAMMA Investing LLC boosted its holdings in Elevance Health by 81,726.5% in the 1st quarter. GAMMA Investing LLC now owns 1,474,514 shares of the company's stock valued at $641,355,000 after purchasing an additional 1,472,712 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Elevance Health by 3.1% in the 1st quarter. Vanguard Group Inc. now owns 22,152,108 shares of the company's stock valued at $9,635,281,000 after purchasing an additional 666,534 shares in the last quarter. Boston Partners boosted its holdings in Elevance Health by 241.3% in the 1st quarter. Boston Partners now owns 856,737 shares of the company's stock valued at $372,039,000 after purchasing an additional 605,689 shares in the last quarter. Finally, Two Sigma Investments LP boosted its holdings in Elevance Health by 247.7% in the 4th quarter. Two Sigma Investments LP now owns 501,494 shares of the company's stock valued at $185,001,000 after purchasing an additional 357,257 shares in the last quarter. Hedge funds and other institutional investors own 89.24% of the company's stock.

Elevance Health Price Performance

Shares of ELV stock traded up $8.59 during midday trading on Monday, reaching $319.00. 3,115,324 shares of the company traded hands, compared to its average volume of 2,222,173. The firm's 50 day simple moving average is $317.92 and its two-hundred day simple moving average is $375.72. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $567.26. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The firm has a market cap of $71.83 billion, a PE ratio of 13.57, a price-to-earnings-growth ratio of 1.17 and a beta of 0.59.

Elevance Health (NYSE:ELV - Get Free Report) last issued its quarterly earnings data on Thursday, July 17th. The company reported $8.84 earnings per share (EPS) for the quarter, missing the consensus estimate of $9.30 by ($0.46). Elevance Health had a return on equity of 17.59% and a net margin of 2.83%.The company had revenue of $49.42 billion for the quarter, compared to analyst estimates of $48.26 billion. During the same quarter in the prior year, the firm earned $10.12 earnings per share. The company's revenue for the quarter was up 14.3% on a year-over-year basis. On average, equities research analysts expect that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 25th. Investors of record on Wednesday, September 10th will be given a dividend of $1.71 per share. This represents a $6.84 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Wednesday, September 10th. Elevance Health's payout ratio is currently 29.11%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ELV. JPMorgan Chase & Co. lowered their price objective on Elevance Health from $472.00 to $384.00 and set an "overweight" rating on the stock in a report on Tuesday, July 22nd. Leerink Partners reaffirmed a "market perform" rating and issued a $310.00 price objective (down previously from $510.00) on shares of Elevance Health in a report on Friday, July 18th. Argus reiterated a "hold" rating on shares of Elevance Health in a research report on Monday, July 21st. Wells Fargo & Company reduced their price target on shares of Elevance Health from $400.00 to $330.00 and set an "overweight" rating for the company in a research report on Friday, August 15th. Finally, Truist Financial reduced their price target on shares of Elevance Health from $500.00 to $440.00 and set a "buy" rating for the company in a research report on Wednesday, July 16th. Twelve analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Elevance Health currently has an average rating of "Moderate Buy" and a consensus target price of $413.81.

Insider Activity at Elevance Health

In related news, CEO Gail Boudreaux acquired 8,500 shares of the business's stock in a transaction that occurred on Friday, July 18th. The stock was purchased at an average cost of $286.94 per share, for a total transaction of $2,438,990.00. Following the transaction, the chief executive officer directly owned 151,020 shares of the company's stock, valued at approximately $43,333,678.80. This trade represents a 5.96% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Susan D. Devore acquired 1,200 shares of the business's stock in a transaction that occurred on Tuesday, August 19th. The shares were bought at an average price of $312.15 per share, with a total value of $374,580.00. Following the completion of the transaction, the director directly owned 3,502 shares in the company, valued at approximately $1,093,149.30. The trade was a 52.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 0.29% of the company's stock.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.